Skip to main content

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

Publication ,  Journal Article
Ellis, MJ; Tao, Y; Young, O; White, S; Proia, AD; Murray, J; Renshaw, L; Faratian, D; Thomas, J; Dowsett, M; Krause, A; Evans, DB; Miller, WR ...
Published in: J Clin Oncol
July 1, 2006

PURPOSE: To investigate the impact of human epidermal growth factor receptor (HER) 1 and HER2 gene amplification on endocrine therapy responsiveness, a fluorescence in situ hybridization (FISH) study was conducted on tumor samples from 305 postmenopausal patients with stage II and III estrogen receptor (ER) -positive (ER > or = 10%) breast cancers treated on two independent neoadjuvant endocrine therapy trials. PATIENTS AND METHODS: FISH analysis focused on HER1 and/or HER2 immunohistochemistry (IHC) -positive patients and a random selection of HER1/2 IHC-negative patients. HER2 FISH status was correlated with response and changes in the proliferation marker Ki67. RESULTS: HER1 was rarely amplified (< 1%), and HER2 amplification was observed in 9.2% of patients. Letrozole response by clinical measurement (71% HER2 FISH positive v 71% HER2 FISH negative), mammogram (44% HER2 FISH positive v 47% HER2 FISH negative), or ultrasound (47% HER2 FISH positive v 54% HER2 FISH negative) was not impaired by HER2 FISH-positive status. In contrast, HER2 FISH-positive tumors showed higher histologic grade (P = .009), higher pretreatment Ki67 (P = .005), and less Ki67 suppression after letrozole when compared with HER2 FISH-negative tumors (P = .0001). Similar observations regarding Ki67 were made in a smaller cohort of tamoxifen-treated tumors. CONCLUSION: Neoadjuvant letrozole is clinically effective in ER-positive HER2 FISH-positive tumors, indicating sensitivity to short-term estrogen deprivation. However, continued proliferation despite ongoing letrozole or tamoxifen treatment in the majority of ER-positive HER2 FISH-positive samples (88%) could imply therapeutic resistance that may manifest later in the clinical course of the disease. Discordance between clinical and biomarker findings in this study serves to emphasize the need for surrogate end point validation in neoadjuvant endocrine trials through correlation with information on long-term outcomes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

July 1, 2006

Volume

24

Issue

19

Start / End Page

3019 / 3025

Location

United States

Related Subject Headings

  • Triazoles
  • Treatment Outcome
  • Receptors, Estrogen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Oncology & Carcinogenesis
  • Nitriles
  • Neoadjuvant Therapy
  • Middle Aged
  • Letrozole
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ellis, M. J., Tao, Y., Young, O., White, S., Proia, A. D., Murray, J., … Dixon, J. M. (2006). Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol, 24(19), 3019–3025. https://doi.org/10.1200/JCO.2005.04.3034
Ellis, Matthew J., Yu Tao, Oliver Young, Sharon White, Alan D. Proia, Julliette Murray, Lorna Renshaw, et al. “Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.J Clin Oncol 24, no. 19 (July 1, 2006): 3019–25. https://doi.org/10.1200/JCO.2005.04.3034.
Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006 Jul 1;24(19):3019–25.
Ellis, Matthew J., et al. “Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.J Clin Oncol, vol. 24, no. 19, July 2006, pp. 3019–25. Pubmed, doi:10.1200/JCO.2005.04.3034.
Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006 Jul 1;24(19):3019–3025.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

July 1, 2006

Volume

24

Issue

19

Start / End Page

3019 / 3025

Location

United States

Related Subject Headings

  • Triazoles
  • Treatment Outcome
  • Receptors, Estrogen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Oncology & Carcinogenesis
  • Nitriles
  • Neoadjuvant Therapy
  • Middle Aged
  • Letrozole